The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade

P. Sini
2005 Clinical Cancer Research  
doi:10.1158/1078-0432.ccr-04-1954 pmid:15958638 fatcat:m7w4ioq5arg4bfmtoeoo7frszy